Identification of specific immune cell subtypes in new coronavirus infected peripheral blood and application of specific immune cell subtypes in new coronavirus infected peripheral blood

Abstract

The invention relates to identification of specific immune cell subtypes in new coronavirus infected peripheral blood and application of the specific immune cell subtypes, and provides immune cell populations and subpopulations which play an important role in occurrence and development of COVID-19 diseases. The first class can be used for T cell immunotherapy, DC cell immunotherapy and B cell immunotherapy of new coronal pneumonia and immunotherapy of old patients; the second class can be used for screening and designing a medicine for inhibiting cytokine storm and a medicine for inhibiting T cell reduction; the third class can be used for diagnosis of new coronal pneumonia.

Description

technical field [0001] The invention belongs to the field of diagnosis of novel coronavirus pneumonia, and in particular relates to the identification and application of specific immune cell subtypes in peripheral blood infected with novel coronavirus. Background technique [0002] Diagnosis of infection with the new coronavirus (SARS-CoV-2) can include diagnosis of pneumonia using computed tomography (CT) and detection of virus in throat swab samples, lower respiratory tract secretions, peripheral blood, or stool by real-time RT-PCR RNA (extracted with SARS-CoV-2 specific primers and probes). According to clinical manifestations, COVID-19 is divided into four types, namely mild, common, severe and critical. Some patients without clinical manifestations but nucleic acid tests are considered asymptomatic patients. Due to the lack of specific drugs against the virus SARS-CoV-2, current clinical treatment of this disease mainly relies on supportive care to reduce inflammation ...

AI Technical Summary

Problems solved by technology

At present, the disease classification and prognosis of COVID-19 patients are mainly based on clinical symptoms (fever, cough and other respiratory symptoms, respiratory rate, oxygen saturation rate, oxygenation index, etc.) Counting, detection of cell inflammatory factor content, etc.), it has a certain lag in disease progression and prognosis analysis and lacks a specific method for the diagnosis of COVID-19. For patients with rapid progression and multiple disease foundations, it cannot meet the current diagnosis and prognosis. Judgment needs

At present, single-cell RNA sequencing (scRNA-seq) is an emerging technology that can effectively study immune mechanisms. Based on 10x Chromium Controller equipment, it can specifically and accurately analyze the transcriptional expression profile of individual cells, with extremely high specificity and sensitivity. A number of related studies using scRNA technology have suggested that there is a relationship between the relative proportion of peripheral blood mononuclear cell populations and antiviral immunity in patients with COVID-19. cell analysis

Images